This hypothesis aligns with prior evidence that butyrate alleviates Proteobacteria-driven colonic immune activation and downregulates IDO1 expression in high-fat diet models [36], and that it can directly inhibit IDO1 [37], suggesting a conserved regulatory mechanism likely operative in our NASH context. This evidence concerns the gene IDO1 and metabolic dysfunction-associated steatohepatitis.